# README — Chunked Source Files for Physical AI Oncology Trial Paper

**Prepared for:** Claude Code Opus 4.7 (1M context)  
**Purpose:** Process these 11 files (10 content chunks + this README) to assist in writing a new physical AI oncology trial paper based on the source paper by Kevin Kawchak.  
**Source paper:** "Accelerating FDA Compliance and Cost Efficiency of *in silico* Clinical Trials via AI Digital Twin Pancreatic Cancer Simulation" (Zenodo DOI: 10.5281/zenodo.17239510)

---

## Overview of the Source Paper

The source paper describes an AI-driven digital twin simulation of a 10-arm Phase II pancreatic ductal adenocarcinoma (PDAC) platform trial. Key contributions include:
- A bidirectional digital twin Python notebook (1,000 patients × 36-month horizon)
- Full ASME V&V 40 / FDA M15 MIDD compliance testing (55 tests)
- Multi-AI model (ChatGPT 5, Gemini 2.5 Pro, Claude Opus 4.1, Grok 3/4) iterative notebook development
- FDA-aligned credibility assessment (Model Risk: Medium; Model Impact: Medium with path to High)
- 4 development standards (14 total prompts) documented in detail

---

## File Index and Detailed Descriptions

### chunk_01_title_abstract.md
**Contents:** Paper title, author information, and complete abstract (all five MIDD abstract sections).  
**Key elements:**
- Title: *Accelerating FDA Compliance and Cost Efficiency of in silico Clinical Trials via AI Digital Twin Pancreatic Cancer Simulation*
- Author: Kevin Kawchak, ChemicalQDevice, San Diego, CA, September 30, 2025
- Abstract sections: Question of Interest, Context of Use, Model Influence (Medium), Consequence of Wrong Decision (Medium), Model Risk (Medium), Model Impact (Medium with path to High)
- MIDD framework per FDA M15 Appendix 1 and ASME V&V 40
- 10-arm PDAC trial parameters (100 pts/arm, 36-month horizon, dt=1 day)
- VV40/FDA test suite summary (V-01 through A-04, 55 total tests)
- External validation arms: MPACT (Arm A), NAPOLI-1 (Arm G), POLO (Arms J/K)

**Correlates to:** chunk_02 (Introduction expands on M15/FDA citations in abstract), chunk_06 (V&V test results referenced in abstract), chunk_07 (UQ/Applicability referenced in abstract), chunk_08 (Limitations/Conclusions address abstract claims)

---

### chunk_02_introduction_methods.md
**Contents:** Full Introduction section (3 paragraphs) and full Methods section (4+ paragraphs with AI tool specifications).  
**Key elements:**
- Introduction: MIDD history (1990s–present), IVIVC modeling (1997), PDUFA VI, ASME V&V 40–2018, M15 guidance (Nov 2024)
- Citations: [03IntroMadabushi], [04IntroCraig], [05IntroGalluppi], [01IntroFDA2023], [02IntroFDA2025]
- Methods: 4 prior Kawchak papers as foundation [18KawchakPDAC, 19KawchakSimPDAC, 20KawchakQSPPDAC]
- Quad AI peer review (ChatGPT, Gemini, Opus, Grok)
- 14-prompt development workflow (Standards 1–4)
- AI tool specifications: ChatGPT 5 DR/High, Gemini 2.5 Pro (Temp=1, budget=32768), Claude Opus 4.1 Extended, Claude Sonnet 4.5 Extended, Grok 3 & 4
- Runtime environment: MacOS 14.5 (23F79), Chrome 139.0.7258.155

**Correlates to:** chunk_01 (Methods implements what Abstract describes), chunk_09 (Standards 1–4 tables provide detailed prompts referenced in Methods), chunk_10/11 (BibTeX entries for all citations used in Introduction and Methods)

---

### chunk_03_section_ii_implementation_table.md
**Contents:** Section II Python Digital Twin Phase II Trial Simulation — full implementation table across four subsections.  
**Key elements:**
- Virtual Trial Design: n_patients=1000, max_months=36, dt=1.0, seed=20260115
- 7 Patient Archetypes (ARCH-01 through ARCH-07) with prevalence percentages
- Biomarker assignments (gBRCA 20%, KRAS-G12C 21%, CD47-high 60%, HA-high 9%)
- 10 treatment arms (A through K, including controls and experimental)
- 11 drugs with Emax/EC50/half-life parameters
- DigitalTwin Class and PatientSimulator Class descriptions
- Lotka-Volterra tumor dynamics, resistance allocation (40% primary, 60% acquired)
- Survival modeling (base hazard=0.0012/day, BRCA ×0.25, post-progression ×5.0)
- Output files: pdac_digital_twin_calibrated_final.csv, patient_logs/, adaptation_log.csv, km_data_by_arm.csv, waterfall_plot_data.csv, adaptation_summary.csv
- Runtime: 13.12 seconds for 1000 patients × 36 months

**Correlates to:** chunk_04 (simulation output uses parameters from this table), chunk_05 (patient adaptation data reflects DigitalTwin Class described here), chunk_06 (dt=1.0 is the reference value tested in temporal convergence), chunk_07 (V&V test parameters reference exact variable names from this table), chunk_08 (Limitations reference simplified Emax PK/PD described here)

---

### chunk_04_results_notebook_output.md
**Contents:** Results Section 3 — complete verbatim simulation console output from the Python notebook execution.  
**Key elements:**
- 38-cycle progress bar with Alive/Progressed counts per cycle (full output)
- Final TRIAL SUMMARY STATISTICS table (10 arms × 8 metrics)
- All arm results: ORR%, DCR%, mPFS (HR), PFS-6%, mOS (HR), OS-12%, G3+%, Drop%
- Key findings: Arm J best mPFS (10.3 mo), Arm J best mOS (21.5 mo), Arm H lowest HR for PFS (0.31)
- Output file confirmation messages
- Runtime: 13.12 seconds (0.22 minutes)
- Digital twin success criteria checklist (4 items confirmed)

**Correlates to:** chunk_03 (parameters that generated this output), chunk_05 (patient-level detail underlying these arm summaries), chunk_06 (dt=1.0 column of temporal convergence table matches this output exactly), chunk_08 (Limitations compares this output to published clinical trial data for arms A and G)

---

### chunk_05_adaptations_swimmer_km_waterfall.md
**Contents:** Results Section 4 — Digital Twin Simulation Adaptations including swimmer plot description, patient adaptation data table (3 patients × all cycles), and KM/Waterfall plot figure descriptions.  
**Key elements:**
- Swimmer plot: 8/1000 patients shown; Longest life = Patient 0002
- Patient 0002: 25 cycles in Arm E (PR throughout), switches to G at Day 588 (PD), BSC at Day 644
- Patient 0008: Discontinued Arm C at Cycle 3 (Grade 3 toxicity), switches to G at Cycle 5
- Patient 0208: Arm C through Cycle 9 (Grade 3 toxicity → BSC), then G (Grade 3 again), BSC survival through Cycle 23
- Event types: Continue current therapy, Disease progression - switch to 2L chemo, Discontinued due to Grade 3+ toxicity, Progressed on last available line or ECOG>1
- KM figure: Simulation Performance Favors Arm J
- Waterfall figure: Best Waterfall Plots: Arm C, Arm J
- Regimen occupancy figure: Most Basic Supportive Care over Time
- Heatmap figure: 1st Line Transitions to 2nd Line: Arm G

**Correlates to:** chunk_03 (DigitalTwin Class behavior shown in patient-level detail), chunk_04 (arm-level summaries correspond to patient-level data shown here), chunk_08 (Conclusions reference swimmer plot as evidence of digital twin functionals)

---

### chunk_06_vv_test_suite_part1_temporal_convergence.md
**Contents:** V&V Test Suite Part 1 full table (Model Verification & Numerical Checks V-01 through V-06; Model Validation & Sensitivity Analysis S-01 through S-09) and three complete temporal convergence tables (dt=0.1, dt=0.5, dt=1.0).  
**Key elements:**
- V-01: dt convergence test (values 0.5, 0.1 vs original 1.0)
- V-02: Seed reproducibility (SEED=12345, 98765 run twice each)
- V-03: Zero-Efficacy (Emax=0.0, 1e-9)
- V-04: Zero-Growth (growth_rate=0.0, -0.001)
- V-05: Mass Balance / Boundary Conditions (code inspection)
- V-06: Toxicity Model Logic (g3_prob=1.0, 0.0)
- S-01 through S-09: Full sensitivity analysis parameters with original values and test values
- Three complete 10-arm result tables at dt=0.1, dt=0.5, dt=1.0 (30 rows of numeric results)
- dt=1.0 table matches exactly the output in chunk_04

**Correlates to:** chunk_01 (Abstract references V-01 through A-04 test IDs), chunk_03 (exact variable names from Section II table referenced in test parameters), chunk_04 (dt=1.0 results column matches main simulation output), chunk_07 (Part 2 continues UQ and Applicability tests), chunk_09 (Data Availability lists all 55 test file counts)

---

### chunk_07_verification_validation_uq_applicability_tables.md
**Contents:** Narrative text for Model Verification & Numerical Checks (3 paragraphs) and Model Validation & Sensitivity Analysis (4 paragraphs), plus V&V Test Suite Part 2 full table (UQ-01 through UQ-03; A-01 through A-04).  
**Key elements:**
- V-01 acceptance: mPFS 4.6 and 4.7 for dt=0.95 and 1.0; mOS 9.3 and 9.3
- V-02 acceptance: boxplots for ORR, mPFS, mOS across seeds confirmed stochastic reproducibility
- V-03/V-04/V-06: Verification confirmed in credibility assessment summary (score 81.9/100)
- S-07 acceptance: positive correlation between G3+ AEs and dropout rate
- S-01 through S-09 acceptance: "Acceptable" score on Uncertainty Quantification gauge (85.75%)
- UQ-01: sigma=0.4 (test: 0.2, 0.8 implied by narrative)
- UQ-02: age_sd=6 (test: 3, 12)
- UQ-03: 10 seeds (1001–1010)
- A-01: ARCH prevalence swaps (Young Fit vs Elderly Frail)
- A-02: Dosing schedule (biweekly: day%14==1; weekly: day%7==1)
- A-03: RECIST threshold (0.10 strict, 0.35 lenient vs original 0.20)
- A-04: max_months (18, 60 vs original 36)

**Correlates to:** chunk_06 (Part 1 test definitions correspond to narrative explanations here), chunk_08 (UQ and Applicability narratives continue in next chunk), chunk_09 (verification/validation scores cited in Conclusions reference figures described here)

---

### chunk_08_uq_applicability_financial_limitations_conclusions.md
**Contents:** Narrative sections for Uncertainty Quantification (4 paragraphs), Applicability Assessment (2 paragraphs), Financial Assessments (figure reference), Limitations and Future Work (4 paragraphs), and Conclusions (3 paragraphs).  
**Key elements:**
- UQ narrative: UQ-03 ORR boxplot from 10 seeds; UQ-01 sigma effect on Arm C/J; PFS-6 uncertainty bands; DCR waterfall calibration limitation
- Applicability narrative: Forest plot confirming A-01/A-03/A-04; A-02 dosing data absent from script
- Financial: Figure 14A — Accelerated FDA Cost Efficiency of a PDAC Digital Twin Simulation
- Limitations: No patient-specific Bayesian updating, simplified Emax PK/PD, no immune compartments, no spatial heterogeneity, no EHR integration, rule-based policy only, no CI/p-values
- External validation gaps: Arm A ORR 21% vs ~23% (OK), mPFS 4.7 vs ~5.5 mo (low), DCR 82% (high); Arm G mPFS 1.8 vs ~3.1 mo (short); Arms J/K farther off
- Future work: Confidence intervals, tighter A/G/J/K calibration, neutrophil-driven toxicity from QSP
- Conclusions: 4 digital twin mechanisms verified; Phase II platform trial design rationale; three prior studies basis [18KawchakPDAC, 19KawchakSimPDAC, 20KawchakQSPPDAC]; Verification score 81.9/100; Validation score 85.75%

**Correlates to:** chunk_01 (Abstract claims verified/refuted in Limitations and Conclusions), chunk_04 (trial output numbers compared against published MPACT/NAPOLI-1/POLO benchmarks), chunk_07 (UQ/Applicability test results narrative continues from tables), chunk_09 (Conclusions reference swimmer plot figure from chunk_05, scores from figures in chunk_07)

---

### chunk_09_data_availability_standards_acknowledgments.md
**Contents:** Data Availability section (36 numbered files at Zenodo), ASME V&V 40 / FDA Standards list (55 numbered tests), Standards 1–4 (Visualizations list), and all four Standards process tables (Prompts 01–14 with full text), Acknowledgments, Ethical Disclosures, Rights and Permissions, About This Study.  
**Key elements:**
- Zenodo data availability: 36 files across 14 prompts including .ipynb, .py, .csv, .docx, .pdf
- 55 V&V tests enumerated with file counts (V-01=4, V-02=5, UQ-03=10, etc.)
- Standards 1–4 files and visualization categories (67 total items)
- **Prompt 01** (Full text): Quad AI code review consolidation
- **Prompt 02** (Full text): Plain text protocol creation from prior QSP study
- **Prompt 03** (Full text): First Python notebook from text protocol
- **Prompt 04** (Full text): Parameter optimization from prior DT log files
- **Prompt 05** (Full text): External validation calibration recommendations for Arm A/G
- **Prompt 06** (Full text): 3-notebook comparison table
- **Prompt 07** (Full text): Bi-directional requirement evaluation across 5 notebooks
- **Prompt 08** (Full text): B1 settings transfer to fix_ops41 baseline
- **Prompt 09** (Full text): TPU v6e-1 optimization
- **Prompt 10** (Full text): VV40/FDA test generation
- **Prompt 11** (Full text): Notebook E comparison
- **Prompt 12** (Full text): Model simplification with projected statistics target
- **Prompt 13** (Full text): Rank 1 notebook analysis
- **Prompt 14** (Full text): Final notebook → text protocol conversion
- Process diagrams for all 4 Standards
- CC BY 4.0 license

**Correlates to:** chunk_02 (Methods describes the same workflow documented in detail here), chunk_10/11 (BibTeX entries [21KawchakDTwinPDAC] is the Zenodo DOI cited in Data Availability), all other chunks (each prompt corresponds to iterative development stages that produced the results in chunks 03–08)

---

### chunk_10_bibtex_references_part1.md
**Contents:** BibTeX entries Part 1 — AI tools and software platforms (Claude, ChatGPT variants, OpenAI models, Anthropic models, Grok, Gemini, Google tools, development tools) and all 21 Kawchak prior works (01Kawchak through 21KawchakDTwinPDAC).  
**Key BibTeX keys directly cited in paper text:**
- `ChatGPT5DR` — GPT-5 Deep Research (used for abstract, Methods)
- `ChatGPT5H` — GPT-5 High (abstract, visualizations)
- `Opus41` — Claude Opus 4.1 Extended (first Python notebook)
- `Sonnet45` — Claude Sonnet 4.5 Extended (LaTeX formatting, financial dashboard)
- `Grok4Fast` — Grok 4 Fast (larger coding tasks)
- `Google_AI_Studio` — Gemini 2.5 Pro settings
- `20KawchakQSPPDAC` — Prior QSP study (primary methodological foundation, cited throughout)
- `19KawchakSimPDAC` — In silico Phase III trial (archetypes, timelines)
- `18KawchakPDAC` — End-to-End PDAC proposals (arm design basis)
- `21KawchakDTwinPDAC` — This paper's Zenodo DOI (Data Availability, About This Study)

**Correlates to:** chunk_02 (all AI tools and prior Kawchak works cited in Introduction/Methods), chunk_08 (citations [18KawchakPDAC, 19KawchakSimPDAC, 20KawchakQSPPDAC] in Conclusions), chunk_09 (Zenodo DOIs in Data Availability)

---

### chunk_11_bibtex_references_part2.md
**Contents:** BibTeX entries Part 2 — GitHub repositories, third-party AI/oncology literature, biopharmaceutical engineering literature, LLM inference/architecture literature, and FDA/Introduction primary references.  
**Key BibTeX keys directly cited in paper text:**
- `01IntroFDA2023` — FDA "Assessing the Credibility of CM&S" (2023) — cited in Introduction and Methods
- `02IntroFDA2025` — FDA "M15 General Principles for MIDD" (2025) — cited in Introduction, Abstract, Methods
- `03IntroMadabushi` — Madabushi 2022 MIDD review — cited in Introduction
- `04IntroCraig` — Craig 2023 virtual clinical trials guide — cited in Introduction
- `05IntroGalluppi` — Galluppi 2024 MIDD paired meeting — cited in Introduction
- GitHub repositories: `GitHub24Jun25` (Digital_Twin_PDAC code repository)
- Large collection of oncology LLM papers (not directly cited in main text but present in references.bib)
- LLM inference and architecture papers (background references)

**Correlates to:** chunk_02 (FDA and MIDD references [01IntroFDA2023], [02IntroFDA2025], [03IntroMadabushi], [04IntroCraig], [05IntroGalluppi] all appear in Introduction and Methods), chunk_01 (FDA/ASME standards cited in Abstract)

---

## Cross-File Correlations Summary

### Methodological Chain (Development Workflow)
chunk_02 (Methods narrative) → chunk_09 (Standards 1–4 detailed prompts) → chunk_03 (resulting implementation parameters) → chunk_04 (simulation output) → chunk_05 (patient-level detail)

### Regulatory Compliance Chain
chunk_01 (Abstract MIDD claims) → chunk_02 (Introduction FDA framework) → chunk_06 (V&V Part 1 tests) → chunk_07 (V&V Part 2 tests + narratives) → chunk_08 (UQ/Applicability + scores in Conclusions)

### External Validation Chain
chunk_03 (Arm A/G/J/K parameter definitions) → chunk_04 (final arm results) → chunk_06 (temporal convergence, dt=1.0 = chunk_04 output) → chunk_08 (Limitations comparison to MPACT/NAPOLI-1/POLO benchmarks)

### Citation Chain
chunk_02 (in-text citations) → chunk_10 (AI tools + Kawchak works BibTeX) + chunk_11 (FDA/intro BibTeX)
chunk_08 (Conclusions citations) → chunk_10 (18/19/20KawchakPDAC BibTeX)
chunk_09 (Data Availability Zenodo DOI) → chunk_10 (21KawchakDTwinPDAC BibTeX)

### Numerical Traceability
- The dt=1.0 column in chunk_06 (temporal convergence) is identical to the trial summary statistics in chunk_04 (simulation output) — this is V-01 test evidence
- Drug parameter names in chunk_03 (e.g., DRUG_PARAMS['gemcitabine']['Emax']) appear verbatim as test parameters in chunk_06 and chunk_07
- Patient archetypes in chunk_03 (ARCH-01 through ARCH-07) are referenced in V&V tests A-01 (population drift) in chunk_07
- The 55 V&V test count in chunk_09 (Data Availability) is the sum of all tests in chunks 06 and 07

---

## Instructions for Claude Code Opus 4.7

When using these files to produce a new physical AI oncology trial paper:

1. **Structural template:** Use chunk_01 (Abstract structure) and chunks 02/03/04/05/06/07/08 (section order) as the document architecture template. The MIDD abstract format (Question of Interest → Context of Use → Model Influence → Consequence → Risk → Impact) is particularly useful for physical AI oncology applications.

2. **Parameter adaptation:** chunk_03's implementation table is the key parameter specification template. Replace PDAC-specific archetypes, drug parameters, and arm definitions with physical AI oncology trial equivalents while preserving the table structure.

3. **V&V test framework:** chunks 06 and 07 provide a complete, FDA-aligned test suite. The V-01 through A-04 test IDs, parameter names, original values, and test values constitute a reusable regulatory testing template.

4. **Prompt engineering:** chunk_09's Standards 1–4 (Prompts 01–14) document the exact iterative AI prompting workflow. For a new study, these prompts can be adapted by replacing PDAC-specific content with physical AI oncology trial content while preserving the development structure.

5. **Citation mapping:** chunks 10–11 provide all BibTeX entries. For new paper citation needs, the FDA primary references (01IntroFDA2023, 02IntroFDA2025, 03IntroMadabushi, 04IntroCraig, 05IntroGalluppi) and Kawchak lineage references (18–21KawchakPDAC) are the most directly applicable.

6. **Numerical benchmarks:** chunk_04 provides the final trial summary statistics table format. chunk_06 provides the three-level temporal convergence format. Both formats are directly reusable for a new trial's results section.

7. **Limitations as checklist:** chunk_08 Limitations section identifies 12+ specific gaps (no Bayesian updating, no immune compartments, no CI/p-values, etc.) that a more advanced physical AI oncology trial should address or explicitly acknowledge.
